目的鉴定骨髓瘤抗原Sp17的HLA-A*0201限制性CTL表位。方法采用超基序和量化基序法预测Sp17的HLA-A*0201限制性CTL表位;用T2细胞亲和力实验和稳定性实验对该表位进行初步鉴定。结果超基序和量化基序法预测得出Sp17抗原的4个CTL表位(LLEGLTREI(19-27)、ILREQPDNI(27-35)、SLLEKREKT(45-53)、KEKEEVAAV(111-119)),亲和力实验结果表明LLEGLTREI(19-27)、ILREQPDNI(27-35)、SLLEKREKT(45-53)有较高亲和力,而KEKEEVAAV(111-119)肽亲和力较低;稳定性实验表明ILREQPDNI(27-35)、SLLEKREKT(45-53)与HLA-A*0201分子结合稳定性较好。结论ILREQPDNI(27-35)、SLLEKREKT(45-53)有可能是骨髓瘤抗原Sa17 HLA-A*0201限制件CTL表位。
Objective To identify HLA-A * 0201-restricted CTL epitopes from multiple myeloma tumor antigen Sp17. Methods The HLA-A * 0201-restricted CTL epitopes were predicted by supermotif combined with quantitative motif, and then evaluated by T2 binding assay and MHC stabilization assay. Results Four candidate nonapeptides were predicted by supermotif combined with quantitative motif. T2 binding assay suggested that among the four peptides. LLEGLTREI(19-27). ILREQPDNI(27-35), and SLLEKREKT(45-53) had higher affinity for HLA-A * 0201 molecular as compared to SLLEKREKT(45-53). Peptides ILREQPDNI(27-35) and SLLEKREKT(45-53) could bind stably with HLA-A * 0201 molecular. Conclusion Peptides ILREQPDNI(27-35) and SLLEKREKT(45-53) may be the HLA-A * 0201-restricted CTL epitopes of Sp17.